Double-blind food challenges in children in general paediatric practice: useful and safe, but not without pitfalls

C J Oole-Groen1, P L P Brand1

  • 1Princess Amalia Children's Clinic, Isala klinieken, PO Box 10400, 8000 GK Zwolle, The Netherlands.

Insights

Double-blind placebo-controlled food challenges (DBPCFC) are safe for diagnosing food allergies in children. Most children tested negative for allergies to cow's milk, egg, soy, and hazelnut, but not peanut.

Area of Science:

  • Allergy and Immunology
  • Pediatric Gastroenterology
  • Clinical Nutrition

Background:

  • Food allergies are a growing concern in pediatric populations.
  • Accurate diagnosis is crucial for effective management and prevention of allergic reactions.
  • Double-blind placebo-controlled food challenges (DBPCFC) are the gold standard for diagnosing food allergies.

Purpose of the Study:

  • To evaluate the safety and efficacy of DBPCFC for common food allergens in a general pediatric setting.
  • To describe the outcomes of DBPCFC in children aged 0-18 years.
  • To identify factors associated with positive DBPCFC results and potential challenges in interpretation.

Main Methods:

  • Conducted DBPCFC for cow's milk, hen's egg, soy, peanut, and hazelnut between 2006 and 2011.
  • Utilized a standardized, double-blind protocol over two hospital admissions with a one-week interval.
  • Included children aged 0-18 years undergoing diagnostic food challenges.

Main Results:

  • 234 DBPCFC were performed in 209 children; most challenges were negative (e.g., cow's milk 57.5%, peanut 40.0%, egg 66.7%).
  • Serious allergic reactions (wheeze, anaphylaxis) were rare (0.9%).
  • Non-specific symptoms complicated interpretation, leading to potential false-positive results in 22.4% of physician-reported positive tests.

Conclusions:

  • DBPCFC can be safely implemented in general hospitals for diagnosing various food allergies in children.
  • The majority of tested children showed negative results, except for peanut allergy.
  • Careful interpretation is needed to avoid misdiagnosis due to non-specific symptoms.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...